This is a multicenter expanded access protocol to provide human leukocyte antigen (HLA) partially-matched third-party allogeneic EBV-CTLs for the treatment of EBV-associated viremia and disease for which there is no comparable or satisfactory alternative therapy to treat the patient's disease or condition. Patients must not be eligible to enroll in clinical trials designed to support the development and marketing approval of Atara EBV-CTLs.